Loading..
  • Vivesto logo
  • Vivesto logo
Vivesto
  • About Us
  • Technology & Pipeline
  • Governance
  • Investors
  • Media
  • Contact
  • About Us
    • CEO corner
    • Organisation
      • Management
      • Board of Directors
    • Partnering
    • Career
      • Vacant positions
    • Sustainability / Corporate Responsibility
  • Technology & Pipeline
    • XR Technology Platform
      • Benefits
      • Therapeutic focus
      • IP protection
    • Commercialized products
      • Apealea
    • Project Pipeline
      • Cantrixil
      • Docetaxel Micellar
    • Research and development
      • XR-18
    • Animal Health
  • Corporate Governance
    • Governance reports
    • General Meeting
    • Management
    • Board of Directors
    • Nomination Committee
    • Remuneration
    • Auditor
    • Code of Conduct
    • Articles of Association
    • Documents
  • Investors
    • The Share
    • Ownership Structure
    • Financial Reports and Presentations
    • Analyst coverage
    • Prospectuses
    • Archive US listing
      • SEC Filings
      • Info regarding delisting of ADS from NASDAQ US
    • Press releases
    • Financial calendar
    • Subscribe
    • Contact
  • Media
    • Press releases
    • Events
    • Subscribe
    • Image Bank
    • Contact
  • Contact
May 25, 2022

Annual General Meeting 2022

The Annual General Meeting of Vivesto AB, Reg. No. 556332-6676 (”Vivesto” or the ”company”) was held on Wednesday, 25 May 2022.

Documents

  • Minutes Annual General Meeting 2022 – Vivesto AB
    Swedish May 31, 2022
  • Press release – Report from Annual General Meeting in Vivesto AB
    English May 25, 2022
  • Notice Of AGM 2022 Vivesto AB
    English April 25, 2022
  • Postal voting form AGM 2022
    English
  • Proxy form AGM 2022
    English
  • Information about proposed Board members prior to the AGM 2022
    English
  • The Nomination Committee’s proposals AGM 2022
    English
  • The Nomination Committee’s reasoned opinion prior to AGM 2022
    English
  • Teckningsoptionsvillkor serie 2022-2025 – Vivesto AB
    Swedish
  • Annual Report 2021
    English April 28, 2022
  • Ersättningsrapport 2021
    Swedish
  • Revisorsyttrande – ersättning till ledande befattningshavare
    Swedish
  • Press release – The Nomination Committee of Vivesto proposes election of new Board members and new Chairman of the Board
    English April 19, 2022
  • Press release – Nomination Committee appointed for the 2022 Annual General Meeting in Oasmia
    English December 2, 2021

Calendar

  • February 22, 2024
    Year-end report January-December 2023
  • February 23, 2024
    Year-end report 2023
  • April 22 - April 26, 2024
    Annual Report publication
All events
  • Corporate Governance
    • Governance reports
    • General Meeting
    • Management
    • Board of Directors
    • Nomination Committee
    • Remuneration
    • Auditor
    • Code of Conduct
    • Articles of Association
    • Documents
Vivesto logo
  • About Us
  • Technology & Pipeline
  • Corporate Governance
  • Investors
  • Media
  • Contact

Vivesto is a research and development company that develops new treatment options for patients suffering from difficult-to-treat cancer.

The company has a portfolio of projects with the potential of offering cancer patients with unmet medical needs new treatment alternatives. Vivesto has a track-record of developing drugs from the preclinical stage, through clinical development to regulatory approval.

Vivesto’s most advanced program Apealea® (paclitaxel micellar) has been granted market approval in the EU as a treatment for adult patients suffering from the first relapse of platinum sensitive epithelial ovarian cancer, or primary peritoneal cancer or fallopian tube cancer. Other clinical development programs include Cantrixil for late-stage ovarian cancer, and Docetaxel micellar, in development for advanced prostate cancer. Moreover, the company is developing Paccal Vet (paclitaxel micellar) for malignant melanoma and hemangiosarcoma in dogs. Vivesto has developed proprietary drug delivery technologies designed to improve solubility of various active pharmaceutical ingredients.

The Share

Follow the share
  • Personal data
  • Cookies

OAS-MA-P-001-SEP2020

Vivesto AB
Vallongatan 1
SE-752 16 Uppsala
Tel +46 18 50 54 40
Fax +46 18 51 08 73
info@vivesto.com